021-51111890
购物车（）
sales@molnova.cn
MCU-i11
CAS No. 902903-59-7
MCU-i11 ( —— )
产品货号. M28985 CAS No. 902903-59-7
MCU-i11 is a novel negative modulator of the MCU, binding MICU1 and impairing muscle cell growth.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥3540 | 有现货 |
|
| 10MG | ￥5233 | 有现货 |
|
| 25MG | ￥7995 | 有现货 |
|
| 50MG | ￥11178 | 有现货 |
|
| 100MG | ￥15066 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称MCU-i11
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述MCU-i11 is a novel negative modulator of the MCU, binding MICU1 and impairing muscle cell growth.
-
产品描述MCU-i11 is a novel negative modulator of the MCU, binding MICU1 and impairing muscle cell growth.(In Vitro):Mitochondrial Ca2+ uptake in mouse embryonic fibroblasts (MEFs), MDA-MB-231, and HEK293T cell lines were measured upon treatment with 10 μM compound. MCU-i11 reduced mitochondrial Ca2+ uptake in all tested cell lines, indicating the existence of a conserved mechanism. MCU-i11 had no effect on cell viability.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体PI3Kδ
-
研究领域——
-
适应症——
化学信息
-
CAS Number902903-59-7
-
分子量532.6
-
分子式C28H28N4O5S
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCCOC1=CC=C(NC(=O)CN2C3=C(C4=C(CN(CC4)C(C)=O)S3)C(=O)N(CC3=CC=CC=C3)C2=O)C=C1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Li F, et al. Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. J Med Chem. 2020 Nov 25;63(22):13973-13993.
产品手册
关联产品
-
PJ34
PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.
-
2,3,8-Tri-O-methylel...
2,3,8-tri-O-Methyl ellagic acid has antimicrobial activity agaist Vibro cholera, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacillus cereus, Escherichia coli.
-
Ginsenoside Rk2
Ginsenoside Rk1 has anti-tumor, and anti-platelet aggregation activities.
